Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 54

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 54
---
 March 31 2025, the Company reported a net other expense of $(360,012) whereas in the same period ended 2024 the Company reported the net other expense of $(43,534) Net other income was primarily driven by the recognition of a Derivative Expense in of $(287,053) in 2025. For the period ended March 31, 2025 the Company also recognized higher interest and amortization expenses as compared to the quarter ended 2024.

<div align='center'>39</div>

Net Loss

The Company recognized an Operating Loss of $ 113,349 during the three months ended March 31, 2025 whereas the Company recognized an Operating Loss of $ 101,071 for the same period ended 2024. The reduction in operating loss is primarily attributable to a reduction in all expense categories other than rent incurred during the period ended 2024 as compared to the quarter ended in 2025.

The Company recognized an Operating Loss of $ 174,727 during the six months ended March 31, 2025 whereas the Company recognized an Operating Loss of $ 223,853 for the same period ended 2024. The reduction in operating loss is primarily attributable to a reduction in all expense categories other than rent incurred during the period ended 2025 as compared to the quarter ended in 2025.

Net Loss is $ 19,354 for the three months ended March 31, 2025 as opposed to a Net Loss of $122,454 for the same period ended 2024. The difference is primarily attributable to the recognition by the Company of a Derivative Gain of $128,963 in 2025.

Net Loss is $ 534,739 For the six months ended March 31, 2025 as opposed to a Net Loss of $267,387 for the same period ended 2024. The difference is primarily attributable to the recognition by the Company of a Derivative Loss of $287,053 recognized in the period ended in 2025.

Working Capital

|                     |     |   | March 31, 2025 |   |     |   | September 30, 2024 |   |
|:--------------------|:----|:--|---------------:|:--|:----|:--|-------------------:|:--|
| Current assets      |     | $ |        151,749 |   |     | $ |            143,351 |   |
| Current liabilities |     |